<i>BRCA1</i> Gene as a Potential Marker for Lung Cancer Therapy.

But at the same time, it has been shown that patients with pathogenic mutations in the tumor, at the level of a pronounced trend, have shorter overall survival compared with the group of patients in whom mutations with unidentified clinical significance were found (11.1 versus 17.9 months, log-rank test p = 0.07) [ 50 ].

also in 237 other papers